share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/06 08:34
Moomoo AI 已提取核心信息
On May 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced a non-binding letter of intent to acquire a private company specializing in innovative CAR-T therapies for cancer treatment. The potential business combination involves a cash purchase price of $20 million, adjusted for the seller's indebtedness, and the issuance of American Depository Shares representing the company's ordinary shares. The total value attributable to the shares at closing is also set at $20 million. Additional payments are contingent upon the seller meeting various development milestones. The terms of the proposed transaction are subject to due diligence, negotiation, and execution of definitive agreements, as well as securing financing and necessary approvals. The acquisition aims to expand TC BioPharm's...Show More
On May 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced a non-binding letter of intent to acquire a private company specializing in innovative CAR-T therapies for cancer treatment. The potential business combination involves a cash purchase price of $20 million, adjusted for the seller's indebtedness, and the issuance of American Depository Shares representing the company's ordinary shares. The total value attributable to the shares at closing is also set at $20 million. Additional payments are contingent upon the seller meeting various development milestones. The terms of the proposed transaction are subject to due diligence, negotiation, and execution of definitive agreements, as well as securing financing and necessary approvals. The acquisition aims to expand TC BioPharm's therapeutic platform, particularly in the treatment of solid tumors and autoimmune diseases. The company's CEO, Bryan Kobel, expressed optimism about the synergies and benefits of the acquisition, which aligns with TC BioPharm's M&A strategy. However, there is no guarantee that the transaction will be completed as contemplated or at all.
2024年5月1日，处于临床阶段的生物技术公司TC BioPharm（Holdings）PLC宣布了一份不具约束力的意向书，收购一家专门从事癌症治疗创新CAR-T疗法的私营公司。潜在的业务合并涉及经卖方债务调整后的2000万美元现金收购价格，以及代表公司普通股的美国存托股票的发行。收盘时归属于股票的总价值也定为2,000万美元。额外付款视卖方是否满足各种开发里程碑而定。拟议交易的条款需要经过尽职调查、谈判和最终协议的执行，以及获得融资和必要的批准。此次收购旨在扩大TC BioPharm的治疗平台，特别是在实体瘤和自身免疫性疾病的治疗方面。该公司首席执行官布莱恩·科贝尔对此次收购的协同效应和收益表示乐观，这符合TC BioPharm的并购战略。但是，无法保证交易会按预期完成或完全完成。
2024年5月1日，处于临床阶段的生物技术公司TC BioPharm（Holdings）PLC宣布了一份不具约束力的意向书，收购一家专门从事癌症治疗创新CAR-T疗法的私营公司。潜在的业务合并涉及经卖方债务调整后的2000万美元现金收购价格，以及代表公司普通股的美国存托股票的发行。收盘时归属于股票的总价值也定为2,000万美元。额外付款视卖方是否满足各种开发里程碑而定。拟议交易的条款需要经过尽职调查、谈判和最终协议的执行，以及获得融资和必要的批准。此次收购旨在扩大TC BioPharm的治疗平台，特别是在实体瘤和自身免疫性疾病的治疗方面。该公司首席执行官布莱恩·科贝尔对此次收购的协同效应和收益表示乐观，这符合TC BioPharm的并购战略。但是，无法保证交易会按预期完成或完全完成。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息